LAM

LAM
Name	LAM
Specialty	Pulmonology, Oncology, Pathology

LAM

Lymphangioleiomyomatosis (abbreviated as LAM) is a rare cystic lung disease that predominantly affects women of reproductive age and is characterized by proliferation of abnormal smooth muscle–like cells in the lungs, lymphatics, and kidneys. It sits at the intersection of pulmonology, Thoracic surgery, Nephrology, Genetics, and Radiology and has been the subject of research at institutions such as National Institutes of Health, Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Landmark studies and consensus statements by organizations like the European Respiratory Society, American Thoracic Society, and patient groups such as LAM Foundation have shaped current understanding and management.

Etymology and abbreviation

The term originates from components referring to lymphatic vessels (Lymphatic system), vascular structures (Angio-), and smooth muscle (Leiomyoma) with the final form established in specialist literature and nomenclatural debates involving authors publishing in journals like The Lancet, New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine, and Chest (journal). Abbreviation practices and diagnostic criteria have been standardized in guidelines produced by European Respiratory Society and task forces convened at meetings such as the American Thoracic Society International Conference.

History and development

Descriptions consistent with LAM appear intermittently in case reports from the early 20th century and were consolidated by pathologists and clinicians working across centers such as Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital in mid-to-late 20th century publications. Advances in imaging at institutions like Memorial Sloan Kettering Cancer Center and molecular genetics research at National Cancer Institute and Harvard Medical School identified links between LAM and mutations in tuberous sclerosis complex genes, prompting collaborations with researchers from Cold Spring Harbor Laboratory and Broad Institute. Clinical trials at centers including Stanford University School of Medicine and University of California, San Francisco led to the repurposing of mTOR inhibitors following pivotal studies reported in journals such as Nature Medicine and Science Translational Medicine.

Types and variations

Clinically recognized categories include sporadic forms and those associated with hereditary syndromes like tuberous sclerosis complex, which involves alterations in TSC1 and TSC2 genes identified by teams at University of Cambridge and University of Toronto. Phenotypic spectrum spans pulmonary-dominant presentations, extrapulmonary lymphatic involvement described at specialty centers including Peter MacCallum Cancer Centre, and renal angiomyolipomas documented by radiologists at Cleveland Clinic and Royal Brompton Hospital. Variants distinguished in literature from groups such as European Reference Network include forms with predominant chylous effusions, clarified in multicenter cohorts from Mount Sinai Hospital and Karolinska Institute.

Clinical presentation and diagnosis

Patients typically present with progressive dyspnea evaluated in clinics at Royal Free Hospital and Guy's Hospital, recurrent pneumothorax managed by teams at Toronto General Hospital, or chylothorax handled at Hammersmith Hospital. Diagnostic algorithms rely on high-resolution computed tomography protocols developed at Johns Hopkins Hospital and consensus statements from American Thoracic Society and European Respiratory Society, supplemented by biomarkers measured in laboratories affiliated with Mayo Clinic and histopathology panels from Memorial Sloan Kettering Cancer Center. Differential diagnosis involves consideration of diseases treated at specialist centers like Mount Sinai Hospital and Scripps Clinic.

Pathophysiology and mechanisms

Key mechanistic insights implicate dysregulation of the mTOR signaling pathway revealed through genetic studies of TSC2 and TSC1 genes by groups at University of Pennsylvania and Yale School of Medicine, with functional studies performed at Massachusetts Institute of Technology and Cold Spring Harbor Laboratory. Cellular behavior resembling neoplastic proliferation with lymphatic invasion links to concepts explored by researchers at Dana–Farber Cancer Institute and Sloan Kettering Institute, while hormonal influences implicating estrogen pathways have drawn endocrine investigators from Imperial College London and University of Oxford. Animal models and cell lines developed in collaborations between National Institutes of Health and academic centers enabled preclinical testing of targeted therapies reported in Nature and Cell.

Management and treatment

Management strategies incorporate pharmacotherapy with mTOR inhibitors such as sirolimus and everolimus evaluated in randomized and open-label trials led by investigators at University of Toronto, Stanford University, and National Institutes of Health; interventions include pleurodesis and surgical options performed in thoracic units at Cleveland Clinic and Brigham and Women's Hospital. Multidisciplinary care often involves transplant teams at UCLA Medical Center and Charité – Universitätsmedizin Berlin for advanced disease, and nephrectomy or embolization for renal angiomyolipomas carried out at UCSF Medical Center and Royal Liverpool University Hospital. Guidelines from European Respiratory Society and consensus documents from American Thoracic Society inform surveillance and reproductive counseling provided by clinics such as John Radcliffe Hospital.

Epidemiology and prognosis

Epidemiological data assembled by registries at National Institutes of Health, European Lung Foundation, and national rare-disease networks indicate that the condition predominantly affects women, with incidence and prevalence estimates reported by groups at University of British Columbia and Aarhus University Hospital. Longitudinal cohorts from Mayo Clinic and Mount Sinai Hospital have clarified factors associated with progression, while outcomes after lung transplantation have been characterized by transplant centers including Toronto General Hospital and Papworth Hospital. Prognosis varies with disease severity, response to mTOR inhibition, and comorbidities managed by specialists at Karolinska University Hospital.

Category:Rare diseases